Physician profile
Peter Sershon
NPI 1104813138
$2,202.32
in general payments reported to CMS, 2019-2025
37 companies · $400 in 2025
The $400 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $325 · 2020: $69.83 · 2021: $207 · 2022: $337 · 2023: $493 · 2024: $371 · 2025: $400.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,264.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,264.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $306.76 | 2020-2025 | Spaceoar Vue System - 10ml, Lithovue, Greenlight Xps |
| Astellas Pharma US INC | $225.82 | 2019-2024 | Myrbetriq, Veozah |
| Dendreon Pharmaceuticals LLC | $129.98 | 2019 | |
| Sumitomo Pharma America, INC. | $119.28 | 2023-2025 | Gemtesa |
| Ethicon INC. | $118.05 | 2019 | |
| Blue Earth Diagnostics | $114.53 | 2021-2024 | |
| Urogen Pharma, INC. | $102.90 | 2021-2025 | Jelmyto |
| Telix Pharmaceuticals | $87.53 | 2025 | Illuccix |
| Intuitive Surgical, INC. | $85.76 | 2020-2023 | Da Vinci Surgical System |
| Tolmar, INC. | $73.49 | 2023-2024 | |
| Urovant Sciences INC | $64.41 | 2022 | |
| Myovant Sciences INC. | $62.25 | 2021-2022 | |
| Calyxo, INC. | $57.52 | 2025 | Cvac Aspiration System |
| Bayer Healthcare Pharmaceuticals INC. | $56.72 | 2022-2023 | |
| Abbvie INC. | $52.30 | 2023-2025 | Lupron Depot |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abc Home Medical Supply, INC. | $49.51 | 2024-2025 | |
| Procept Biorobotics Corporation | $42.68 | 2023 | Aquabeam Robotic System |
| C. R. Bard, INC. & Subsidiaries | $42.53 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $42.03 | 2022-2023 | Opdivo |
| Laborie Medical Technologies Corp. | $39.73 | 2024-2025 | Optilume Bph Drug Coated Balloon Catheter |
| Astrazeneca Pharmaceuticals Lp | $36.45 | 2023-2024 | |
| Inspire Medical Systems, INC. | $32.62 | 2024 | Inspire |
| Amgen INC. | $28.68 | 2020-2022 | |
| Axonics, INC. | $23.94 | 2024 | Axonics, Bulkamid |
| Coloplast Corp | $21.92 | 2024 | |
| Agiliti Surgical, INC. | $19.87 | 2024 | Sonablate Hifu, Endocare Cryocare Cs System, Koelis Trinity Fusion Biopsy System |
| Ferring Pharmaceuticals INC. | $19.40 | 2025 | Adstiladrin |
| Teleflex LLC | $18.00 | 2024 | Urolift |
| Merck Sharp & Dohme LLC | $17.73 | 2021 | |
| Medtronic, INC. | $16.32 | 2025 | Altaviva |
| Endo Pharmaceuticals INC. | $15.50 | 2022 | |
| Janssen Biotech, INC. | $15.39 | 2021 | |
| Myriad Genetic Laboratories, INC. | $14.64 | 2022 | |
| Profound Medical Corp. | $14.23 | 2022 | |
| Pfizer INC. | $13.32 | 2022 | |
| Antares Pharma, INC. | $11.85 | 2021 | |
| Edap Technomed INC | $8.68 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Sershon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.